Medication errors associated with over-the-counter drugs: Prevalence and reduction strategies

Journal of Pharmaceutical Finance, Economics and Policy

Volumn 15, Issue 4, 2007, Pages 109-144

  Wertheimer, Albert I ^a   Santella, Thomas M ^b  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b Lannett Pharmaceuticals   (United States)

Author keywords

OTC drug errors; OTC drug problems

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANTACID AGENT; BISACODYL; CALCIUM; IBUPROFEN; LEVOTHYROXINE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

ALLERGY; ANALGESIA; ARTICLE; ASTHMA; COUGHING; DIARRHEA; DRUG APPROVAL; DRUG SAFETY; DRUG USE; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEARTBURN; HOSPITAL ADMISSION; HOSPITAL PATIENT; MEDICAL PRACTICE; MEDICATION ERROR; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE; PATIENT MONITORING; PATIENT SAFETY; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SELF MEDICATION; SLEEP DISORDER; SMOKING CESSATION; TREATMENT INDICATION; UNITED STATES; WEIGHT REDUCTION;

EID: 34948874777     PISSN: 15385698     EISSN: 15385396     Source Type: Journal    
DOI: 10.1300/J371v15n04_05     Document Type: Article

References (47)

1. Consumer Use of OTC Medications and Dietary Supplements. 2002. Rodale Inc.
2. Schultz, S. July 1998. New labels could give needed information. U.S. News and World Report.
3. The National Institute of Medicine. 2000. To err is human. National Academy Press: Washington.
4. Heffler, S., Smith, S., Keehan, S., Clemens, K. M., Zezza, M., and Christopher T. February 2004. Trends: Health spending projections through 2013. Health Affairs Web Exclusive, W479-W493., http://www.healthaffairs.org/ contents-by-date.O.shtml
5. FDA Center for Drug Evaluation and Research Handbook. Available online at www.fda.gov
6. Federal Trade Commission [16 CFR Part 451]. Reprinted from the Federal Registrar of April 6, 1976-41 F.R. 14534.
7. Schultz, p. 2.
8. Traynor, K. March 2005. Report urges scientific standards for alternative medicine. American Society of Health-System Pharmacy 62(6):562-568.
9. United States General Accounting Office - Testimony before the Subcommittee on Human Resources and Intergovernmental Relations Committee on Governmental Operations, House of Representative. Nonprescription drugs - Over the counter and underemphasized - Statement of Kwai-Cheung Chan. April 8, 1992.
10. AESGP-Economic and legal framework for non-prescription medicines. June 2003.
11. Traynor, K. April 1, 2004. FDA to require bar coding of most pharmaceuticals by mid-2006: Lot number, expiration date not required in bar code. American Journal of Health-System Pharmacy 61(7): 644-645.
12. Roark, D.C. January 2004. Bar Codes and Drug Administration: Can new technology reduce the number of medication errors? American Journal of Nursing 104(1):63-66.
13. FDA Safety Center Authority would extend to OTCs under Grassley bill. The Tan Sheet. May 2, 2005
14. Frank C. et al. June 2001. What drugs are our frail elderly patients taking? Do drugs they take or fail to take put them at increased risk of interactions and inappropriate medication use? Canadian Family Physician 47:1198-1204.
15. Simaon, H.K. and Winkle, D.A. July 1997. Over-the-counter medications: Do parents give what they intend to give? Archives of Pediatrics and Adolescent Medicine 151(7):654-656.
16. Jaski, M.E., Schwartzberg, J.G., Guttman R.A., and Noorani, M. Jan-Feb 2000. Medication review and documentation in physician office practice. Effective Clinical Practice 3(1):31-34.
17. Muller, C. May 1972. The Overmedicated Society: Forces in the Marketplace for Medical Care. Science 176:488-492.
18. Morrison, T. May 23, 2005. Counter Intelligence. Business Week. Pp. 116-117.
19. Patel V.L., Branch T., and Arocha J.F. November 12, 2002. Errors in interpreting quantities as procedures: The case of pharmaceutical labels. International Journal of Medical Informatics 65(3):193-211.
20. Neafsey, P.J. and Shellman, J. September 2002. Knowledge and self-efficacy of community health nurses concerning interactions of prescription medicines with over-the-counter agents and alcohol. Journal of Gerontological Nursing 28(9):30-39.
21. Bradley, J.D. and Brandt, K.D. 1991. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. JAMA 325:87-91.
22. Singh, G., Ramey, D.R., Morfeld, D., Shi, H., Haroum, H.T., and Fries, J.F. 1996. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study. Archives of Internal Medicine 156:1530-1536.
23. D'Arcy, P.F. and McElnay, J.C. 1987. Drug-antacid interactions: Assessment of clinical importance. Drug Intelligence in Clinical Pharmacy 21(7/8):607-617.
24. Espino, D.V. and Lancaster, M.C. 1992. Neutralization of the effects of captopril by the use of ibuprofen in elderly women. Journal of the American Board of Family Practice 5(3):319-321.
25. Houston, M.C. 1991. Nonsteroidal anti-inflammatory drugs and antihypertensives. American Journal of Medicine 190(Suppl. 5A): 42S-47S.
26. Bakris, G. and Kern, S. 1989. Renal dysfunction resulting from NSAIDs. American Family Physician 40:199-204.
27. Lamy, P. 1986. Renal effects of NSAIDs. Journal of the American Geriatric Society 34:361-367.
28. Rex, D.K. and Kumar, S. 1992. Recognizing acetaminophen hepatotoxicity in chronic alcoholics. Postgraduate Medicine 91:241-245.
29. Zimmerman, H.J. and Maddrey, W.C. 1995. Acetaminophen hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure. Hepatology 22:767-773.
30. Johnson J.A. and Bootman J.L. 1995. Drug related morbidity and mortality. A cost-of-illness model. Archives of Internal Medicine 155(18):1949-1956.
31. Ibid.
32. Classen, David C. et al. January 22/29, 1997. Adverse drug events in hospitalized patients. JAMA 277(4):301-306.
33. Andrews L.B. et al. 1997. An alternative strategy for studying adverse events in medical care. Lancet 349:309-313.
34. Bates D.W., Spell N. et al. 1997. The costs of adverse drug events in hospitalized patients. JAMA 277(4):307-311.
35. Schneitman-McIntire O., Farnen T.A. et al. 1996. Medication misadventures resulting in emergency department visits at an HMO medical center. American Journal of Health-System Pharmacy 53:1416-1422.
36. Dennehy C.E., Kishi D.T., and Loiue C. 1996. Drug-related illness in emergency department patients. American Journal of Health-System Pharmacy 53: 1422-1426.
37. Schneider P.J., Gift M.G. et al. 1995. Cost of medication-related problems at a university hospital. American Journal of Health-System Pharmacy 52:2415-2418.
38. Fine A. and Park R.E. 1987. Assuring the quality of health care for older persons. JAMA 258:1905-1908.
39. FDA. 64 Fed. Reg. 13277 (March 17, 1999).
40. Ives T.J., Bentz E.J., and Gwyther R.E. 1987. Drug-related admissions to a family medicine inpatient service. Archives of Internal Medicine 147:1117-1120.
41. Caranasps G.J., Stewart R.B., and Cluff, L.E. 1991. Drug-induced illness leading to hospitalization. Med Care 29:193-200.
42. Mitchell A.A., Lacouture P.G., Sheehan J.E., Kauffman R.E., and Shapiro S. 1988. Adverse drug reactions in children leading to hospital admission. Pediatrics 82:24-29.
43. The Degge Group, Ltd. November 1, 1995. Over-the-counter medications and drug interactions - A current public health and epidemiological perspective.
44. Department of Health and Human Services, Food and Drug Administration. August 24, 1995. Prescription drug product labeling: Medication guide requirements. Federal Register 60(164). Specifically citing The Drug Abuse Warning Network, Annual Emergency Room Data, 1992. U.S. Department of Health and Human Services; Substance Abuse and Mental Health Services Administration, Series I, Number 12-A:44.
45. Personal Communication. May, 19, 2005. Consumer Healthcare Products Association. Douglas Bierer, PhD, Vice President-Regulatory and Scientific Affairs; David Spangler, Vice President-International and Assistant General Counsel.
46. United States General Accounting Office, Report to the Ranking Minority Member, Committee on Commerce, House of Representatives. August 1995. Nonprescription drugs-Value of a pharmacist-controlled class has yet to be demonstrated, pp.79-80.
47. Personal Communication. May 19, 2005. Consumer Healthcare Products Association. Douglas Bierer, Ph.D, Vice President-Regulatory and Scientific Affairs; David Spangler, Vice President-International and Assistant General Counsel.